Arcutis Biotherapeutics has spent the weeks since the FDA approval of its topical plaque psoriasis cream Zoryve strengthening its cash position, drawing down $125 million from its loan facility and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback